Novel allogeneic cellular therapies predictions for the future
On-demand panel discussion link
Description
Over the last several years, there has been increasing global investment in the development of novel allogeneic cell and gene therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 allogeneic cellular therapies are under development across the globe, many of which are focused on hematological malignancies that have traditionally been treated with BMT and HCT (The Clinical Pipeline for Cancer Cell Therapies, Nature Reviews Drug Discovery, June 2021)
While the majority of emerging therapies are autologous, there is rapid growth in the clinical development of allogeneic approaches that might one day offer either a replacement or complement to autologous approaches. In this session, a panel of industry and clinical experts will explore the promise and risks associated with allogeneic cell therapy approaches.
Learning Objectives
- Current trends in the development of emerging allogeneic cell therapies
- Benefits and risks associated with emerging allogeneic cell therapies
- Prediction on how the development of allogeneic approaches may complement or replace current autologous therapies and BMT/HSCT.
Target Audience
Physicians, medical directors
Speakers
- Sarah Cooley, MD, MS, Senior Vice President, Clinical Translation, Fate Therapeutics
- Stephen Gottschalk, MD, Chair of the Department of Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Research Hospital
- Stephan Grupp, MD, PhD, Chief of the Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia
- Chris McClain, Senior Vice President, Sales - Commercial Entities, NMDP BioTherapies®